Literature DB >> 33972393

Nuclear Lamin A/C Expression Is a Key Determinant of Paclitaxel Sensitivity.

Elizabeth R Smith1, Justin Leal2, Celina Amaya2, Bing Li1, Xiang-Xi Xu1,2.   

Abstract

Paclitaxel is a key member of the Taxane (paclitaxel [originally named taxol], docetaxel/Taxotere) family of successful drugs used in the current treatment of several solid tumors, including ovarian cancer. The molecular target of paclitaxel has been identified as tubulin, and paclitaxel binding alters the dynamics and thus stabilizes microtubule bundles. Traditionally, the anticancer mechanism of paclitaxel has been thought to originate from its interfering with the role of microtubules in mitosis, resulting in mitotic arrest and subsequent apoptosis. However, recent evidence suggests that paclitaxel operates in cancer therapies via an as-yet-undefined mechanism rather than as a mitotic inhibitor. We found that paclitaxel caused a striking break up of nuclei (referred to as multimicronucleation) in malignant ovarian cancer cells but not in normal cells, and susceptibility to undergo nuclear fragmentation and cell death correlated with a reduction in nuclear lamina proteins, lamin A/C. Lamin A/C proteins are commonly lost, reduced, or heterogeneously expressed in ovarian cancer, accounting for the aberration of nuclear shape in malignant cells. Mouse ovarian epithelial cells isolated from lamin A/C-null mice were highly sensitive to paclitaxel and underwent nuclear breakage, compared to control wild-type cells. Forced overexpression of lamin A/C led to resistance to paclitaxel-induced nuclear breakage in cancer cells. Additionally, paclitaxel-induced multimicronucleation occurred independently of cell division that was achieved by either the withdrawal of serum or the addition of mitotic inhibitors. These results provide a new understanding for the mitotis-independent mechanism for paclitaxel killing of cancer cells, where paclitaxel induces nuclear breakage in malignant cancer cells that have a malleable nucleus but not in normal cells that have a stiffer nuclear envelope. As such, we identify that reduced nuclear lamin A/C protein levels correlate with nuclear shape deformation and are a key determinant of paclitaxel sensitivity of cancer cells.

Entities:  

Keywords:  drug resistance; lamin A/C; micronuclei; microtubule; mitosis; mitotic inhibitor; multimicronucleation; nuclear envelope; nuclear lamina; ovarian cancer; paclitaxel

Mesh:

Substances:

Year:  2021        PMID: 33972393      PMCID: PMC8224231          DOI: 10.1128/MCB.00648-20

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  53 in total

1.  Focus on epithelial ovarian cancer.

Authors:  Robert F Ozols; Michael A Bookman; Denise C Connolly; Mary B Daly; Andrew K Godwin; Russell J Schilder; Xiangxi Xu; Thomas C Hamilton
Journal:  Cancer Cell       Date:  2004-01       Impact factor: 31.743

Review 2.  Salvage therapy for recurrent epithelial ovarian cancer.

Authors:  Vicki V Baker
Journal:  Hematol Oncol Clin North Am       Date:  2003-08       Impact factor: 3.722

Review 3.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

Review 4.  Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.

Authors:  Edina Komlodi-Pasztor; Dan L Sackett; Antonio Tito Fojo
Journal:  Clin Cancer Res       Date:  2012-01-01       Impact factor: 12.531

5.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.

Authors:  M A Jordan; R J Toso; D Thrower; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

6.  Nuclear envelope structural defects cause chromosomal numerical instability and aneuploidy in ovarian cancer.

Authors:  Callinice D Capo-chichi; Kathy Q Cai; Fiona Simpkins; Parvin Ganjei-Azar; Andrew K Godwin; Xiang-Xi Xu
Journal:  BMC Med       Date:  2011-03-26       Impact factor: 8.775

7.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

8.  Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy.

Authors:  T Sullivan; D Escalante-Alcalde; H Bhatt; M Anver; N Bhat; K Nagashima; C L Stewart; B Burke
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

Review 9.  Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?

Authors:  T J Mitchison; J Pineda; J Shi; S Florian
Journal:  Open Biol       Date:  2017-11       Impact factor: 6.411

Review 10.  Defective Nuclear Lamina in Aneuploidy and Carcinogenesis.

Authors:  Elizabeth R Smith; Callinice D Capo-Chichi; Xiang-Xi Xu
Journal:  Front Oncol       Date:  2018-11-20       Impact factor: 6.244

View more
  4 in total

Review 1.  Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity.

Authors:  Celina Amaya; Elizabeth R Smith; Xiang-Xi Xu
Journal:  J Cancer       Date:  2022-04-18       Impact factor: 4.478

Review 2.  The microtubule cytoskeleton: An old validated target for novel therapeutic drugs.

Authors:  Laurence Lafanechère
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

Review 3.  Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel.

Authors:  Elizabeth R Smith; Marilyn Huang; Matthew P Schlumbrecht; Sophia H L George; Xiang-Xi Xu
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

4.  Breaking malignant nuclei as a non-mitotic mechanism of taxol/paclitaxel.

Authors:  Elizabeth R Smith; Xiang-Xi Xu
Journal:  J Cancer Biol       Date:  2021
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.